|
US6773669B1
(en)
|
1995-03-10 |
2004-08-10 |
Maxcyte, Inc. |
Flow electroporation chamber and method
|
|
US6090617A
(en)
|
1996-12-05 |
2000-07-18 |
Entremed, Inc. |
Flow electroporation chamber with electrodes having a crystalline metal nitride coating
|
|
US6534261B1
(en)
|
1999-01-12 |
2003-03-18 |
Sangamo Biosciences, Inc. |
Regulation of endogenous gene expression in cells using zinc finger proteins
|
|
CA2407695C
(en)
|
2000-04-28 |
2015-03-31 |
Sangamo Biosciences, Inc. |
Methods for binding an exogenous molecule to cellular chromatin
|
|
US7029916B2
(en)
|
2001-02-21 |
2006-04-18 |
Maxcyte, Inc. |
Apparatus and method for flow electroporation of biological samples
|
|
CN1302115C
(zh)
|
2001-04-23 |
2007-02-28 |
埃麦克萨有限公司 |
电穿孔用缓冲溶液及上述溶液的使用方法
|
|
AU2002326717A1
(en)
|
2001-08-22 |
2003-03-10 |
Maxcyte, Inc. |
Apparatus and method for electroporation of biological samples
|
|
GB0124391D0
(en)
|
2001-10-11 |
2001-11-28 |
Gene Expression Technologies L |
Control of gene expression
|
|
US20050136040A1
(en)
|
2001-10-11 |
2005-06-23 |
Imperial College Innovations Limited |
Control of gene expression using a complex of an oligonucleotide and a regulatory peptide
|
|
WO2003080809A2
(en)
|
2002-03-21 |
2003-10-02 |
Sangamo Biosciences, Inc. |
Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
|
|
ITMI20030821A1
(it)
|
2003-04-18 |
2004-10-19 |
Internat Ct For Genetic En Gineering And |
Polipeptidi chimerici e loro uso.
|
|
US20060182736A1
(en)
|
2003-06-10 |
2006-08-17 |
Kim Jin-Soo |
Transducible dna-binding proteins
|
|
US8133733B2
(en)
|
2003-10-24 |
2012-03-13 |
Gencia Corporation |
Nonviral vectors for delivering polynucleotides to target tissues
|
|
DE502004009820D1
(de)
|
2004-03-15 |
2009-09-10 |
Lonza Cologne Ag |
Behältnis und Vorrichtung zur Erzeugung von elektrischen Feldern in einzelnen Reaktionsräumen
|
|
US7771984B2
(en)
|
2004-05-12 |
2010-08-10 |
Maxcyte, Inc. |
Methods and devices related to a regulated flow electroporation chamber
|
|
JP4519915B2
(ja)
|
2004-06-12 |
2010-08-04 |
インビトロゲン シンガポール ピーティーイー．リミテッド． |
中空構造を有する電気穿孔装置
|
|
ES2465467T3
(es)
|
2004-06-14 |
2014-06-05 |
Lonza Cologne Ag |
Procedimiento y disposición de circuito para el tratamiento de material biológico
|
|
US20070254291A1
(en)
|
2004-06-14 |
2007-11-01 |
Xiaoxia Cui |
Gene Targeting in Eukaryotic Cells by Group II Intron Ribonucleoprotein Particles
|
|
US7991559B2
(en)
|
2004-11-30 |
2011-08-02 |
Maxcyte Inc. |
Computerized electroporation
|
|
US10022457B2
(en)
|
2005-08-05 |
2018-07-17 |
Gholam A. Peyman |
Methods to regulate polarization and enhance function of cells
|
|
DK2341149T3
(en)
|
2005-08-26 |
2017-02-27 |
Dupont Nutrition Biosci Aps |
Use of CRISPR-associated genes (Cas)
|
|
BRPI0716427A2
(pt)
|
2006-08-11 |
2014-03-11 |
Dow Agrosciences Llc |
Recombinação homóloga mediada por nuclease de apêndice de zinco
|
|
US8450112B2
(en)
|
2008-04-09 |
2013-05-28 |
Maxcyte, Inc. |
Engineering and delivery of therapeutic compositions of freshly isolated cells
|
|
US20120088842A1
(en)
|
2008-07-18 |
2012-04-12 |
Maxcyte, Inc. |
Methods for optimizing electroporation
|
|
US20110239315A1
(en)
|
2009-01-12 |
2011-09-29 |
Ulla Bonas |
Modular dna-binding domains and methods of use
|
|
EP2424877A4
(en)
|
2009-04-28 |
2013-01-02 |
Harvard College |
SUPRAGELADENE PROTEINS FOR CELL PENETRATION
|
|
WO2011059836A2
(en)
|
2009-10-29 |
2011-05-19 |
Trustees Of Dartmouth College |
T cell receptor-deficient t cell compositions
|
|
US8956828B2
(en)
*
|
2009-11-10 |
2015-02-17 |
Sangamo Biosciences, Inc. |
Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
|
|
WO2011072246A2
(en)
|
2009-12-10 |
2011-06-16 |
Regents Of The University Of Minnesota |
Tal effector-mediated dna modification
|
|
US9567573B2
(en)
|
2010-04-26 |
2017-02-14 |
Sangamo Biosciences, Inc. |
Genome editing of a Rosa locus using nucleases
|
|
US8876458B2
(en)
|
2011-01-25 |
2014-11-04 |
United Technologies Corporation |
Blade outer air seal assembly and support
|
|
US10391126B2
(en)
|
2011-11-18 |
2019-08-27 |
Board Of Regents, The University Of Texas System |
CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA
|
|
GB201122458D0
(en)
|
2011-12-30 |
2012-02-08 |
Univ Wageningen |
Modified cascade ribonucleoproteins and uses thereof
|
|
US20130236504A1
(en)
|
2012-03-06 |
2013-09-12 |
Medical University Of South Carolina |
Delivery System for Enhancing Drug Efficacy
|
|
AU2013266968B2
(en)
|
2012-05-25 |
2017-06-29 |
Emmanuelle CHARPENTIER |
Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
|
|
AU2013335451C1
(en)
|
2012-10-23 |
2024-07-04 |
Toolgen Incorporated |
Composition for cleaving a target DNA comprising a guide RNA specific for the target DNA and Cas protein-encoding nucleic acid or Cas protein, and use thereof
|
|
PL3360964T3
(pl)
|
2012-12-06 |
2020-03-31 |
Sigma-Aldrich Co. Llc |
Modyfikacja i regulacja genomu oparta na crispr
|
|
EP2840140B2
(en)
|
2012-12-12 |
2023-02-22 |
The Broad Institute, Inc. |
Crispr-Cas based method for mutation of prokaryotic cells
|
|
EP2931899A1
(en)
|
2012-12-12 |
2015-10-21 |
The Broad Institute, Inc. |
Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
|
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
|
DK2931891T3
(da)
|
2012-12-17 |
2019-08-19 |
Harvard College |
Rna-styret modificering af menneskelige genomer
|
|
KR20150132479A
(ko)
*
|
2013-03-15 |
2015-11-25 |
어댑티브 바이오테크놀로지스 코포레이션 |
복합 유전자 세트에서의 독특하게 태그되고 재배열된 적응 면역 수용체 유전자
|
|
CN112301024A
(zh)
|
2013-03-15 |
2021-02-02 |
通用医疗公司 |
使用RNA引导的FokI核酸酶(RFN)提高RNA引导的基因组编辑的特异性
|
|
US9937207B2
(en)
*
|
2013-03-21 |
2018-04-10 |
Sangamo Therapeutics, Inc. |
Targeted disruption of T cell receptor genes using talens
|
|
CA2908403A1
(en)
|
2013-04-02 |
2014-10-09 |
Bayer Cropscience Nv |
Targeted genome engineering in eukaryotes
|
|
WO2014191128A1
(en)
*
|
2013-05-29 |
2014-12-04 |
Cellectis |
Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
|
|
ES2883131T3
(es)
|
2013-05-29 |
2021-12-07 |
Cellectis |
Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN
|
|
US9526784B2
(en)
|
2013-09-06 |
2016-12-27 |
President And Fellows Of Harvard College |
Delivery system for functional nucleases
|
|
WO2015048690A1
(en)
|
2013-09-27 |
2015-04-02 |
The Regents Of The University Of California |
Optimized small guide rnas and methods of use
|
|
EP3441468B1
(en)
|
2013-10-17 |
2021-05-19 |
Sangamo Therapeutics, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
|
CA2930590C
(en)
|
2013-11-15 |
2021-02-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Engineering neural stem cells using homologous recombination
|
|
JP7103750B2
(ja)
|
2013-12-12 |
2022-07-20 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
ゲノム編集のためのＣＲＩＳＰＲ－Ｃａｓ系及び組成物の送達、使用及び治療適用
|
|
EP3470089A1
(en)
|
2013-12-12 |
2019-04-17 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components
|
|
JP6793547B2
(ja)
|
2013-12-12 |
2020-12-02 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
最適化機能ＣＲＩＳＰＲ−Ｃａｓ系による配列操作のための系、方法および組成物
|
|
US20160304893A1
(en)
|
2013-12-13 |
2016-10-20 |
Cellectis |
Cas9 nuclease platform for microalgae genome engineering
|
|
EP3099801B1
(en)
|
2014-01-31 |
2020-03-18 |
Factor Bioscience Inc. |
Synthetic rna for use in the treatment of dystrophic epidermolysis bullosa
|
|
WO2015115903A1
(en)
|
2014-02-03 |
2015-08-06 |
Academisch Ziekenhuis Leiden H.O.D.N. Lumc |
Site-specific dna break-induced genome editing using engineered nucleases
|
|
WO2015161276A2
(en)
|
2014-04-18 |
2015-10-22 |
Editas Medicine, Inc. |
Crispr-cas-related methods, compositions and components for cancer immunotherapy
|
|
EP3188763B1
(en)
|
2014-09-02 |
2020-05-13 |
The Regents of The University of California |
Methods and compositions for rna-directed target dna modification
|
|
JP2017529841A
(ja)
*
|
2014-09-19 |
2017-10-12 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
キメラ抗原受容体
|
|
WO2016049251A1
(en)
|
2014-09-24 |
2016-03-31 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling mutations in leukocytes
|
|
US9879283B2
(en)
|
2014-10-09 |
2018-01-30 |
Life Technologies Corporation |
CRISPR oligonucleotides and gene editing
|
|
US20170335331A1
(en)
*
|
2014-10-31 |
2017-11-23 |
The Trustees Of The University Of Pennsylvania |
Altering Gene Expression in CART Cells and Uses Thereof
|
|
WO2016097751A1
(en)
|
2014-12-18 |
2016-06-23 |
The University Of Bath |
Method of cas9 mediated genome engineering
|
|
JP2018509387A
(ja)
|
2015-01-21 |
2018-04-05 |
フェーズアールエックス インコーポレイテッド |
細胞に治療および診断剤を送達するための方法、組成物、ならびにシステム
|
|
WO2016123578A1
(en)
|
2015-01-30 |
2016-08-04 |
The Regents Of The University Of California |
Protein delivery in primary hematopoietic cells
|
|
WO2016135559A2
(en)
|
2015-02-23 |
2016-09-01 |
Crispr Therapeutics Ag |
Materials and methods for treatment of human genetic diseases including hemoglobinopathies
|
|
CN107614012A
(zh)
|
2015-04-24 |
2018-01-19 |
加利福尼亚大学董事会 |
使用工程化的细胞检测、监测或治疗疾病或病况的系统及制备和使用它们的方法
|
|
WO2016196388A1
(en)
|
2015-05-29 |
2016-12-08 |
Juno Therapeutics, Inc. |
Composition and methods for regulating inhibitory interactions in genetically engineered cells
|
|
JP2018518181A
(ja)
|
2015-06-17 |
2018-07-12 |
ザ ユーエービー リサーチ ファンデーション |
血液細胞系列の細胞に機能的ポリペプチドを導入するためのＣＲＩＳＰＲ／Ｃａｓ９複合体
|
|
JP2018518182A
(ja)
|
2015-06-17 |
2018-07-12 |
ザ ユーエービー リサーチ ファンデーション |
ゲノム編集のためのｃｒｉｓｐｒ／ｃａｓ９複合体
|
|
US20170000743A1
(en)
|
2015-07-02 |
2017-01-05 |
Vindico NanoBio Technology Inc. |
Compositions and Methods for Delivery of Gene Editing Tools Using Polymeric Vesicles
|
|
AU2016291778B2
(en)
|
2015-07-13 |
2021-05-06 |
Sangamo Therapeutics, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
|
US9512446B1
(en)
|
2015-08-28 |
2016-12-06 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
|
US20180243446A1
(en)
|
2015-09-01 |
2018-08-30 |
The Hospital For Sick Children |
Method and compositions for removing duplicated copy number variaions (cnvs) for genetic disorders and related uses
|
|
US20190119350A1
(en)
|
2015-09-09 |
2019-04-25 |
Immune Design Corp. |
Ny-eso-1 specific tcrs and methods of use thereof
|
|
WO2017053729A1
(en)
|
2015-09-25 |
2017-03-30 |
The Board Of Trustees Of The Leland Stanford Junior University |
Nuclease-mediated genome editing of primary cells and enrichment thereof
|
|
EP3356533A1
(en)
|
2015-09-28 |
2018-08-08 |
North Carolina State University |
Methods and compositions for sequence specific antimicrobials
|
|
EP3359660B1
(en)
*
|
2015-10-05 |
2019-12-04 |
Precision Biosciences, Inc. |
Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene
|
|
JP6816133B2
(ja)
*
|
2015-10-05 |
2021-01-20 |
プレシジョン バイオサイエンシズ，インク． |
改変ヒトｔ細胞受容体アルファ定常領域遺伝子を含む遺伝子改変細胞
|
|
US20180327706A1
(en)
|
2015-10-19 |
2018-11-15 |
The Methodist Hospital |
Crispr-cas9 delivery to hard-to-transfect cells via membrane deformation
|
|
EP3365454A1
(en)
|
2015-10-20 |
2018-08-29 |
10X Genomics, Inc. |
Methods and systems for high throughput single cell genetic manipulation
|
|
WO2017070429A1
(en)
|
2015-10-22 |
2017-04-27 |
Regents Of The University Of Minnesota |
Methods involving editing polynucleotides that encode t cell receptor
|
|
KR20250141836A
(ko)
|
2015-11-04 |
2025-09-29 |
페이트 세러퓨틱스, 인코포레이티드 |
만능 세포의 유전자 조작
|
|
CA3005968A1
(en)
|
2015-11-23 |
2017-06-01 |
The Regents Of The University Of California |
Tracking and manipulating cellular rna via nuclear delivery of crispr/cas9
|
|
EP3389677B1
(en)
*
|
2015-12-18 |
2024-06-26 |
Sangamo Therapeutics, Inc. |
Targeted disruption of the t cell receptor
|
|
CA3009715A1
(en)
|
2015-12-30 |
2017-07-06 |
Avectas Limited |
Vector-free delivery of gene editing proteins and compositions to cells and tissues
|
|
JP2019509738A
(ja)
*
|
2016-03-11 |
2019-04-11 |
ブルーバード バイオ， インコーポレイテッド |
ゲノム編集された免疫エフェクター細胞
|
|
US20190161530A1
(en)
|
2016-04-07 |
2019-05-30 |
Bluebird Bio, Inc. |
Chimeric antigen receptor t cell compositions
|
|
EP4711465A2
(en)
|
2016-04-14 |
2026-03-18 |
Fred Hutchinson Cancer Center |
Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
|
|
US10188749B2
(en)
|
2016-04-14 |
2019-01-29 |
Fred Hutchinson Cancer Research Center |
Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
|
|
EP4628587A3
(en)
*
|
2016-04-15 |
2026-02-25 |
Memorial Sloan Kettering Cancer Center |
Transgenic t cell and chimeric antigen receptor t cell compositions and related methods
|
|
WO2017189336A1
(en)
|
2016-04-25 |
2017-11-02 |
The Regents Of The University Of California |
Methods and compositions for genomic editing
|
|
EP4166660A1
(en)
|
2016-04-29 |
2023-04-19 |
BASF Plant Science Company GmbH |
Improved methods for modification of target nucleic acids using fused guide rna - donor molecules
|
|
US20190136224A1
(en)
|
2016-05-31 |
2019-05-09 |
Massachusetts Institute Of Technology |
Hydrodynamically Controlled Electric Fields for High Throughput Transformation & High Throughput Parallel Transformation Platform
|
|
EP3472338B1
(en)
|
2016-06-20 |
2024-05-22 |
Octapharma AG |
Means and methods for modifying multiple alleles
|
|
WO2018035387A1
(en)
|
2016-08-17 |
2018-02-22 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
|
US11999931B2
(en)
|
2016-08-20 |
2024-06-04 |
The Regents Of The University Of California |
High-throughput system and method for the temporary permeabilization of cells
|
|
CN110291100B
(zh)
|
2016-10-12 |
2024-06-11 |
费尔丹生物公司 |
用于将多肽负荷从细胞外空间递送至靶真核细胞的胞质溶胶和/或细胞核的合理设计的合成肽穿梭剂，其用途、与其相关的方法和试剂盒
|
|
WO2018073391A1
(en)
|
2016-10-19 |
2018-04-26 |
Cellectis |
Targeted gene insertion for improved immune cells therapy
|
|
WO2018073393A2
(en)
|
2016-10-19 |
2018-04-26 |
Cellectis |
Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
|
|
WO2018094291A1
(en)
|
2016-11-18 |
2018-05-24 |
Christopher Bradley |
Massively multiplexed homologous template repair for whole-genome replacement
|
|
AU2017378427A1
(en)
|
2016-12-14 |
2019-06-20 |
Ligandal, Inc. |
Methods and compositions for nucleic acid and protein payload delivery
|
|
CN110546495B
(zh)
|
2016-12-30 |
2022-11-01 |
加利福尼亚州立大学董事会 |
用于基因组编辑t细胞的选择和传代的方法
|
|
WO2018232356A1
(en)
|
2017-06-15 |
2018-12-20 |
The Regents Of The University Of California |
Targeted non-viral dna insertions
|
|
JP7101419B2
(ja)
*
|
2017-10-27 |
2022-07-15 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
内因性ｔ細胞受容体の標的置換
|
|
SG11202004026QA
(en)
*
|
2017-10-30 |
2020-05-28 |
Pact Pharma Inc |
Primary cell gene editing
|